13-36865660-G-A
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 16P and 4B. PVS1PP5_Very_StrongBS2
The NM_001127217.3(SMAD9):c.880C>T(p.Arg294*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000291 in 1,613,936 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001127217.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SMAD9 | NM_001127217.3 | c.880C>T | p.Arg294* | stop_gained | 5/7 | ENST00000379826.5 | NP_001120689.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SMAD9 | ENST00000379826.5 | c.880C>T | p.Arg294* | stop_gained | 5/7 | 5 | NM_001127217.3 | ENSP00000369154.4 | ||
SMAD9 | ENST00000350148.10 | c.769C>T | p.Arg257* | stop_gained | 4/6 | 1 | ENSP00000239885.6 | |||
SMAD9 | ENST00000399275.7 | n.*479C>T | non_coding_transcript_exon_variant | 4/6 | 1 | ENSP00000382216.3 | ||||
SMAD9 | ENST00000399275.7 | n.*479C>T | 3_prime_UTR_variant | 4/6 | 1 | ENSP00000382216.3 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152110Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251470Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135912
GnomAD4 exome AF: 0.0000308 AC: 45AN: 1461826Hom.: 0 Cov.: 32 AF XY: 0.0000261 AC XY: 19AN XY: 727228
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152110Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74316
ClinVar
Submissions by phenotype
Pulmonary hypertension, primary, 2 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Nov 15, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Mar 09, 2023 | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 56970). This premature translational stop signal has been observed in individual(s) with clinical features of SMAD9-related conditions (PMID: 21920918, 29631995, 29650961). This variant is present in population databases (rs397514716, gnomAD 0.002%). This sequence change creates a premature translational stop signal (p.Arg294*) in the SMAD9 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SMAD9 are known to be pathogenic (PMID: 19419974, 31727138). - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 15, 2011 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 23, 2017 | The R294X pathogenic variant in the SMAD9 gene has been reported previously in association with PAH (Drake et al., 2011). In vitro analysis of the R294X variant shows that this pathogenic variant causes a primary defect in noncanonical SMAD-mediated microRNA processing, consistent with a loss-of-function effect on the protein (Drake et al., 2011). R294X is predicted to cause loss of normal protein function either by protein truncation or nonsense-mediated mRNA decay. One other nonsense mutation in the SMAD9 gene has been reported in association with PAH. Furthermore, the R294X variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. In summary, R294X in the SMAD9 gene is interpreted as a pathogenic variant.This variant was found in PAH-ARRHYTHMIA - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at